Clinical evaluation of a new anthelmintic - C. 9333 Go./CGP 4540 in human hookworm infection.
A new antihookworm compound, C.9333 Go./CGP 4540, was evaluated clinically in 65 adult patients with hookworm infection. Several dosage schedules were evaluated to determine an effective, well tolerated and convenient regime. The lowest effective dose was 125 mg administered at four-hourly intervals for three doses. The compound was generally well tolerated; mild giddiness was observed in nine patients and severe giddiness was present in one patient. Clinical and biochemical monitoring revealed no other toxicity of the compound.
D000722:Ancylostoma / Q000187:drug effects; D000814:Aniline Compounds / Q000627:therapeutic use*; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004159:Diphenylamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004341:Drug Evaluation; D005243:Feces / Q000469:parasitology; D005260:Female; D006725:Hookworm Infections / Q000188:drug therapy*; D006801:Humans; D017879:Isothiocyanates; D008297:Male; D009331:Necator / Q000187:drug effects; D010270:Parasite Egg Count; D013861:Thiocyanates / Q000008:administration & dosage / Q000627:therapeutic use*
D000814:Aniline Compounds; D000871:Anthelmintics; D017879:Isothiocyanates; D013861:Thiocyanates; D004159:Diphenylamine; C012391:amoscanate